Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1. Cue Biopharma appointed Dr. Daniel Baker as interim chief development officer. 2. Dr. Baker received an inducement option for 200,000 shares at $1.06 each. 3. The option vests over two years, contingent on continued employment. 4. This appointment aligns with Cue's focus on innovative immunotherapy development.